全文获取类型
收费全文 | 6603篇 |
免费 | 407篇 |
国内免费 | 28篇 |
专业分类
耳鼻咽喉 | 42篇 |
儿科学 | 223篇 |
妇产科学 | 166篇 |
基础医学 | 1078篇 |
口腔科学 | 94篇 |
临床医学 | 442篇 |
内科学 | 1203篇 |
皮肤病学 | 227篇 |
神经病学 | 702篇 |
特种医学 | 217篇 |
外国民族医学 | 5篇 |
外科学 | 941篇 |
综合类 | 38篇 |
预防医学 | 318篇 |
眼科学 | 177篇 |
药学 | 467篇 |
中国医学 | 2篇 |
肿瘤学 | 696篇 |
出版年
2023年 | 49篇 |
2022年 | 84篇 |
2021年 | 122篇 |
2020年 | 83篇 |
2019年 | 104篇 |
2018年 | 127篇 |
2017年 | 100篇 |
2016年 | 134篇 |
2015年 | 156篇 |
2014年 | 191篇 |
2013年 | 248篇 |
2012年 | 328篇 |
2011年 | 359篇 |
2010年 | 190篇 |
2009年 | 189篇 |
2008年 | 326篇 |
2007年 | 292篇 |
2006年 | 318篇 |
2005年 | 322篇 |
2004年 | 278篇 |
2003年 | 281篇 |
2002年 | 234篇 |
2001年 | 231篇 |
2000年 | 212篇 |
1999年 | 188篇 |
1998年 | 82篇 |
1997年 | 74篇 |
1996年 | 61篇 |
1995年 | 32篇 |
1994年 | 52篇 |
1993年 | 36篇 |
1992年 | 105篇 |
1991年 | 89篇 |
1990年 | 86篇 |
1989年 | 77篇 |
1988年 | 91篇 |
1987年 | 84篇 |
1986年 | 71篇 |
1985年 | 56篇 |
1984年 | 45篇 |
1983年 | 39篇 |
1982年 | 32篇 |
1979年 | 52篇 |
1975年 | 31篇 |
1974年 | 41篇 |
1973年 | 36篇 |
1972年 | 33篇 |
1971年 | 32篇 |
1969年 | 30篇 |
1966年 | 46篇 |
排序方式: 共有7038条查询结果,搜索用时 15 毫秒
1.
2.
Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma
3.
Erythropoietin(EPO) is one of the most successful biopharmaceuticals in history and is used for treating anemia of different origins. However, it became clear that EPO could also work in a neuroprotective, antiapoptotic, antioxidative, angiogenetic and neurotropic way. It causes stimulation of cells to delay cell apoptosis, especially in the central nervous system. In rodent models of focal cerebral ischemia, EPO showed an impressive reduction of infarct size by 30% and improvement of neurobehavioral outcome by nearly 40%. A large animal model dealing with ischemia and reperfusion of the spinal cord showed that EPO could reduce the risk of spinal cord injury significantly. In addition, some clinical studies tested whether EPO works in real live clinical settings. One of the most promising studies showed the innocuousness and improvements in follow-up, outcome scales and in infarct size, of EPO-use in humans suffering from ischemic stroke. Another study ended unfortunately in a negative outcome and an increased overall death rate in the EPO group. The most possible reason was the involvement of patients undergoing simultaneously systemic thrombolysis with recombinant tissue plasminogen activator. An experimental study on rats demonstrated that administration of EPO might exacerbate tissue plasminogen activator-induced brain hemorrhage without reducing the ischemic brain damage. This case shows clearly how useful animal models can be to check negative side effects of a treatment before going into clinical trials. Other groups looked in human trials at the effects of EPO on the outcome after ischemic stroke, relation to circulating endothelial progenitor cells, aneurysmal subarachnoid hemorrhage, traumatic brain injury, hemoglobin transfusion thresholds and elective first-time coronary artery bypass surgery. Most of the results were positive, but are based mostly on small group sizes. However, some of the most neglected facts when focusing on experimental setups of ischemia of the central nervous system are issues like age and comorbidities. It might be extremely worthy to consider these points for future projects, because EPO might influence all these factors. 相似文献
4.
U. Bolm-Audorff S. Brandenburg T. Brüning H. Dupuis R. Ellegast G. Elsner K. Franz H. Grasshoff V. Grosser L. Hanisch B. Hartmann E. Hartung K. G. Hering G. Heuchert M. Jäger J. Krämer Dr. A. Kranig E. Ludolph A. Luttmann A. Nienhaus W. Pieper K.-D. Pöhl T. Remé D. Riede G. Rompe K. Schäfer S. Schilling E. Schmitt F. Schröter A. Seidler M. Spallek M. Weber 《Trauma und Berufskrankheit》2005,7(3):211-252
Occupational diseases Nos. 2108 and 2110 correspond to intervertebral disc-related diseases of the lumbar spine from many years of carrying or lifting heavy loads, occupations in extreme postures of full flexion or oscillation of the whole body when seated, and which compel the cessation of all activities which are or could be the cause for the origin, exacerbation or recurrence of the disease. These occupational diseases came into force at the start of 1993, but there have been considerable problems in their implementation. The present Part I of the contribution is the result of the work of an interdisciplinary study group and contains medical criteria for the assessment of possibly strain-related clinical characteristics and the evaluation of other possible causes. Part II is to be published in Volume 4/2005 and will deal with questions related to forced cessation and to the assessment of the loss of earning ability. Agreement was reached in many areas related to the assessment of occupational claims. This should allow for evidence-based decision making in the future for the occupational diseases Nos. 2108 and 2110. 相似文献
5.
C. Bokemeyer K. Oechsle J.-T. Hartmann 《European journal of clinical investigation》2005,35(S3):26-31
6.
Dr. Arthur Hartmann 《Langenbeck's archives of surgery / Deutsche Gesellschaft fur Chirurgie》1878,9(1-2):74-83
Ohne Zusammenfassung 相似文献
7.
8.
Sandra Urdaneta Hartmann Brian Wigdahl Elizabeth B Neely Cheston M Berlin Cara-Lynne Schengrund Hung-Mo Lin Mary K Howett 《Journal of human lactation》2006,22(1):61-74
Reduction of transmission of human immunodeficiency virus type 1 (HIV-1) through human milk is needed. Alkyl sulfates such as sodium dodecyl sulfate (SDS) are microbicidal against HIV-1 at low concentrations, have little to no toxicity, and are inexpensive. The authors have reported that treatment of HIV-1-infected human milk with < or = 1% (10 mg/mL) SDS for 10 minutes inactivates cell-free and cell-associated virus. The SDS can be removed with a commercially available resin after treatment without recovery of viral infectivity. In this article, the authors report results of selective biochemical analyses (ie, protein, immunoglobulins, lipids, cells, and electrolytes) of human milk subjected to SDS treatment and removal. The SDS treatment or removal had no significant effects on the milk components studied. Therefore, the use of alkyl sulfate microbicides to treat milk from HIV-1-positive women may be a simple, practical, and nutritionally sound way to prevent or reduce transmission of HIV-1 while still feeding with mother's own milk. 相似文献
9.
Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients 总被引:1,自引:0,他引:1
A. Åsberg A. Humar H. Rollag A. G. Jardine H. Mouas M. D. Pescovitz D. Sgarabotto M. Tuncer I. L. Noronha A. Hartmann 《American journal of transplantation》2007,7(9):2106-2113
Intravenous ganciclovir is the standard treatment for cytomegalovirus disease in solid organ transplant recipients. Oral valganciclovir is a more convenient alternative. In a randomized, international trial, recipients with cytomegalovirus disease were treated with either 900 mg oral valganciclovir or 5 mg/kg i.v. ganciclovir twice daily for 21 days, followed by 900 mg daily valganciclovir for 28 days. A total of 321 patients were evaluated (valganciclovir [n = 164]; i.v. ganciclovir [n = 157]). The success rate of viremia eradication at Day 21 was 45.1% for valganciclovir and 48.4% for ganciclovir (95% CI -14.0% to +8.0%), and at Day 49; 67.1% and 70.1%, respectively (p = NS). Treatment success, as assessed by investigators, was 77.4% versus 80.3% at Day 21 and 85.4% versus 84.1% at Day 49 (p = NS). Baseline viral loads were not different between groups and decreased exponentially with similar half-lives and median time to eradication (21 vs. 19 days, p = 0.076). Side-effects and discontinuations of assigned treatment (18 of 321 patients) were comparable. Oral valganciclovir shows comparable safety and is not inferior to i.v. ganciclovir for treatment of cytomegalovirus disease in organ transplant recipients and provides a simpler treatment strategy, but care should be taken in extrapolating to organ transplant recipients not properly represented in the present study. 相似文献
10.
U. Bolm-Audorff S. Brandenburg T. Brüning H. Dupuis R. Ellegast G. Elsner K. Franz H. Grasshoff V. Grosser L. Hanisch B. Hartmann E. Hartung† K. G. Hering G. Heuchert M. Jäger J. Krämer Dr. A. Kranig E. Ludolph A. Luttmann A. Nienhaus W. Pieper K. D. Pöhl T. Remé D. Riede G. Rompe K. Schäfer S. Schilling E. Schmitt F. Schröter A. Seidler M. Spallek M. Weber 《Trauma und Berufskrankheit》2005,7(4):320-332
The first part of this serial paper dealt with the medical criteria used in evaluation of the clinical picture caused by physical stress and the evaluation of other candidate causes and was published in issue no. 3/2005 (pp. 711–752) of Trauma and Berufskrankheit. This follow-up paper (II) presents criteria to be used in the evaluation of whether it is necessary to give up the occupations putting the spine at risk and in estimation of the degree of disability. 相似文献